Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Christopher Daugherty and Richard A. Larson.

 
Connection Strength
 
 
 
0.514
 
  1. Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.114
  2. Odenike OM, Sobecks RM, Janisch L, Huo D, Zimmerman TM, Daugherty CK, Ratain MJ, Larson RA. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
    View in: PubMed
    Score: 0.077
  3. Siston AK, List MA, Daugherty CK, Banik DM, Menke C, Cornetta K, Larson RA. Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001 Jun; 27(11):1181-8.
    View in: PubMed
    Score: 0.061
  4. Cataland SR, Daugherty CK, Weseman EC, Larson RA. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Apr; 41(3-4):297-307.
    View in: PubMed
    Score: 0.060
  5. Sobecks RM, Daugherty CK, Hallahan DE, Laport GF, Wagner ND, Larson RA. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. Bone Marrow Transplant. 2000 Apr; 25(8):807-13.
    View in: PubMed
    Score: 0.056
  6. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Sep; 20(5):369-74.
    View in: PubMed
    Score: 0.047
  7. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.032
  8. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.024
  9. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.022
  10. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.